Translate this page into:
Letter to the Editor
doi:
10.4103/sajc.sajc_199_18
Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
1
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
2
Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra
*Corresponding author: Dr. Kumar Prabhash. kprabhash1@gmail.com
MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
References
- Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial. Lancet Oncol 2016;17:234-42.
- Mezquita L, Besse B. Sequencing ALK inhibitors: Alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al. J Thorac Dis 2016;8:2997-3002.
- Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: A phase II global study. J Clin Oncol 2016;34:661-8.